Google
Trusted Resources: News & Events
Latest announcements and gatherings
Sickle Cell Groups, Pfizer Work to Bring African-Americans into Clinical Trials
It’s been nearly half a century since the end of Alabama’s Tuskegee experiment, the infamous 40-year study in which the U.S. government intentionally gave 399 syphilis-infected black men useless placebos — like aspirin and mineral supplements — instead of penicillin, which could have cured them.
Yet suspicions still linger, complicating today’s efforts to recruit African-Americans into clinical trials for sickle cell disease (SCD), which disproportionately affects black people.
Pfizer, with the help of the Sickle Cell Disease Association of America, is trying to change that.
The New York-based pharma giant, which is now recruiting for its own clinical trials in sickle cell disease, recently launched oneSCDvoice, a collaborative digital platform aimed at educating and lending emotional support to people with SCD.
+myBinderRelated Content
-
Emmaus Life Sciences, Inc. to present results of phase 3 study of endariTM (L-glutamine oral powder) at 59th America...Emmaus will present results of a Phase 3...
-
A Phase 3 Randomized Trial of Voxelotor in Sickle Cell DiseaseBackground: Deoxygenated sickle hemog...
-
The Influence of Perceived Racial Bias and Health-Related Stigma on Quality of Life Among Children With Sickle Cell ...Objectives: Individuals with sickle ce...
-
Kids With Sickle Cell Anemia are More Sedentary Than Healthy Peers, Study SuggestsChildren and adolescents with sickle cel...
-
Novo Nordisk obtains licence for sickle cell disease programNovo Nordisk inked a global licence deal...
-
Phase 1 trial to test under-the-skin injection of sevuparin in sickle cell patientsModus Therapeutics is going to launch ...
-
Imara Reports Favorable Preclinical and Phase 1 Data on IMR-687 in Sickle Cell DiseaseImara Inc. today announced it will repor...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.